PTC Therapeutics executive exercises options, sells shares

Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan.

Rhea-AI Filing Summary

Neil Gregory Almstead, Chief Technical Ops Officer of PTC Therapeutics, exercised stock options to acquire 2,464 common shares at $46.54 and on the same day sold 2,464 shares at a weighted average of $90.25 per share under a pre-arranged Rule 10b5-1 plan. Following these transactions, he holds 60,299 shares directly, 2,899 shares indirectly through his spouse, and 45,036 stock options granted January 3, 2025 that vest over four years and expire January 2, 2035.

Filing Explained

The filing records a same-day 2,464-share option exercise and sale, leaving 45,036 options and 60,299 direct common shares.

The July 13, 2026 Form 4 reports that PTC Therapeutics’ chief technical operations officer exercised 2,464 stock options and sold 2,464 common shares on July 9, 2026. The disclosed consequence is a change in the reporting person’s holdings, including 60,299 direct common shares, 2,899 indirect shares held by a spouse, and 45,036 options remaining.

Under the supplied Form 4 definitions, code M denotes an option or derivative exercise and code S denotes an open-market sale; the filing says the sale was executed under a written Rule 10b5-1 plan adopted on November 11, 2025, which identifies the plan’s adoption date rather than reasons for this individual trade.

The filing reports a weighted-average sale price of $90.25, with individual sales ranging from $90.00 to $90.70, and an option exercise price of $46.54.

Sources and calculations

• PTC Therapeutics Form 4 insider transaction (2026-07-13)
• Form 4 purpose and transaction codes (undated)
• Rule 10b5-1 plan definition (undated)

Insider Trade Summary 10b5-1

Exercise and Sale: 2,464 shares ($108K approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Almstead Neil Gregory

Role CHIEF TECHNICAL OPS OFFICER

Sold 2,464 shs ($222K)

Approx. gross sale proceeds $222K

Approx. exercise cost $115K

Approx. pre-tax spread $108K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F3	2,464	$0.00	$0.00
Exercise	Common Stock F1	2,464	$46.54	$115K
Sale	Common Stock F1, F2	2,464	$90.25	$222K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 45,036 contracts (Direct); Common Stock — 60,299 shares (Direct); Common Stock — 2,899 shares (Indirect, By Spouse)

Footnotes (3)

1. F1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.
2. F2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
3. F3. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.

Key Figures

Shares sold: 2,464 shares Sale price (weighted average): $90.25 per share Options exercised: 2,464 shares +5 more

8 metrics

Shares sold 2,464 shares Common stock sold in open-market transaction on 2026-07-09

Sale price (weighted average) $90.25 per share Weighted average price; trades ranged from $90.00 to $90.70 per share

Options exercised 2,464 shares Common shares acquired upon stock option exercise on 2026-07-09

Exercise price $46.54 per share Exercise price of stock options converted into common stock

Direct holdings after transactions 60,299 shares Common shares held directly by Neil Almstead after July 9, 2026 activity

Indirect holdings via spouse 2,899 shares Common shares beneficially owned indirectly through spouse

Remaining stock options 45,036 shares Stock options (right to buy) remaining after exercise; expiration 2035-01-02

10b5-1 plan adoption date November 11, 2025 Date Neil Almstead adopted the written Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 plan, weighted average price, Stock Option (Right to Buy), vesting

4 terms

Rule 10b5-1 plan regulatory

"This transaction was effected pursuant to a written Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average price financial

"This price represents the weighted average price of sale transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vesting financial

"vests over four years, with 25% of the shares underlying the option vesting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PTC Therapeutics (PTCT) officer Neil Almstead report?

Neil Almstead reported exercising 2,464 stock options at $46.54 per share and selling 2,464 common shares at a weighted average of $90.25 on July 9, 2026, as part of an open-market sale sequence following the option exercise.

How many PTC Therapeutics (PTCT) shares did Neil Almstead sell and at what price?

Almstead sold 2,464 shares of PTC Therapeutics common stock at a weighted average price of $90.25 per share, with individual trades executed between $90.00 and $90.70 per share, according to the reported sale details for July 9, 2026.

What stock options did Neil Almstead exercise in PTCT on July 9, 2026?

He exercised 2,464 stock options with an exercise price of $46.54 per share, converting them into an equal number of common shares. These options were granted on January 3, 2025, vest over four years, and are scheduled to expire on January 2, 2035.

What are Neil Almstead’s PTC Therapeutics (PTCT) holdings after the reported transactions?

After the reported transactions, Almstead holds 60,299 common shares of PTC Therapeutics directly, plus 2,899 shares indirectly through his spouse. He also retains 45,036 stock options (rights to buy additional shares) outstanding following the July 9, 2026 activity.

Was Neil Almstead’s PTC Therapeutics (PTCT) share sale made under a Rule 10b5-1 plan?

Yes. The sale of 2,464 shares on July 9, 2026 was carried out under a written Rule 10b5-1 plan that Almstead adopted on November 11, 2025, indicating the transactions were pre-arranged rather than timed at his sole discretion.

How do Neil Almstead’s option grants in PTCT vest over time?

The stock option grant reported for Almstead was made on January 3, 2025 and vests over four years. 25% vests on January 3, 2026, with an additional 6.25% of the original option amount vesting at the end of each three-month period beginning April 3, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/13/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Almstead Neil Gregory

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNICAL OPS OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		2,464	A	$46.54	62,763	D
Common Stock	07/09/2026		S(1)		2,464	D	$90.25(2)	60,299	D
Common Stock								2,899	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$46.54	07/09/2026		M(1)			2,464	(3)	01/02/2035	Common Stock	2,464	$0	45,036	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on November 11, 2025.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $90.00 to $90.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.

	/s/ Avraham S. Adler, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)